Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00040443
Status:
COMPLETED
Last Update Posted:
2018-07-23
First Post:
2002-06-26
Brief Title:
Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment
Sponsor:
RespireRx
Organization:
RespireRx
Study Overview
Official Title:
Efficacy And Safety Of CX516 900 mg tid In Elderly Participants With Mild Cognitive Impairment A Randomized Double-Blind Placebo-Controlled Parallel-Group 4-week Study
Status:
COMPLETED
Status Verified Date:
2017-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Glutamate is fundamentally involved in learning and memory Memory loss associated with mild cognitive impairment may be due to loss of glutamate receptors in the aging brain There is evidence CX516 enhances brain activity by specifically targeting remaining glutamate receptors in the affected portions of the brain This study will test the safety and efficacy of CX516 in the symptomatic treatment of participants with mild cognitive impairment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None